Christopher G C A Jackson
Overview
Explore the profile of Christopher G C A Jackson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
52
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Signal V, Smith M, Costello S, Davies A, Dawkins P, Jackson C, et al.
Cancer Causes Control
. 2024 Aug;
35(12):1497-1507.
PMID: 39150625
Background: Lung cancer is a deadly cancer. Early diagnosis and access to timely treatment are essential to maximizing the likelihood of survival. Indigenous peoples experience enduring disparities in lung cancer...
2.
Gurney J, Davies A, Stanley J, Whitehead J, Costello S, Dawkins P, et al.
Support Care Cancer
. 2024 Feb;
32(3):171.
PMID: 38378932
Purpose: Centralisation of lung cancer treatment can improve outcomes, but may result in differential access to care for those who do not reside within treatment centres. Methods: We used national-level...
3.
Gurney J, Davies A, Stanley J, Cameron L, Costello S, Dawkins P, et al.
JCO Glob Oncol
. 2024 Feb;
10:e2300258.
PMID: 38301179
Purpose: Lung cancer is the biggest cancer killer of indigenous peoples worldwide, including Māori people in New Zealand. There is some evidence of disparities in access to lung cancer treatment...
4.
Dai M, Chao T, Chiu C, Lu Y, Shiah H, Jackson C, et al.
Ther Adv Med Oncol
. 2023 Jul;
15:17588359231183680.
PMID: 37492633
Background: Paclitaxel is widely used for the treatment of metastatic breast cancer (MBC). However, it has a low oral bioavailability due to gut extrusion caused by P-glycoprotein (P-gp). Oral paclitaxel...
5.
Mason K, Kelly L, Jackson C, Read D, Borman B
N Z Med J
. 2022 Jul;
135(1558):90-95.
PMID: 35834837
Melanoma is one of the most common cancers diagnosed in New Zealand, and New Zealand has one of the highest rates of melanoma incidence and mortality in the world. Monitoring...
6.
He J, Jackson C, Deva S, Hung T, Clarke K, Segelov E, et al.
CPT Pharmacometrics Syst Pharmacol
. 2022 Apr;
11(7):867-879.
PMID: 35470967
Oraxol consists of an oral dosage form of the chemotherapeutic agent paclitaxel administered with a novel P-glycoprotein inhibitor encequidar methanesulfonate monohydrate (formerly named HM30181A), which allows oral treatment of cancers...
7.
McPhail S, Swann R, Johnson S, Barclay M, Abd Elkader H, Alvi R, et al.
Lancet Oncol
. 2022 Apr;
23(5):587-600.
PMID: 35397210
Background: Greater understanding of international cancer survival differences is needed. We aimed to identify predictors and consequences of cancer diagnosis through emergency presentation in different international jurisdictions in six high-income...
8.
Jackson C, Hung T, Segelov E, Barlow P, Prenen H, McLaren B, et al.
Br J Clin Pharmacol
. 2021 May;
87(12):4670-4680.
PMID: 33960504
Aims: Paclitaxel is a widely used anti-neoplastic agent but has low oral bioavailability due to gut extrusion by P-glycoprotein (P-gp). Oral paclitaxel could be more convenient, less resource intensive, and...
9.
Jackson C, Morris T, Hung N, Hung T
Br J Cancer
. 2019 Aug;
121(5):421-424.
PMID: 31363168
Breast cancer can be diagnosed during pregnancy and in the peri-partum period, and the potential exposure of a foetus or neonate to chemotherapy is of concern to mothers and clinicians....
10.
Jackson C, Sharples K, Thompson P, ODonnell A, Robinson B, Perez D, et al.
BMC Cancer
. 2014 Oct;
14:737.
PMID: 25274181
Background: Dose intense chemotherapy may improve efficacy with acceptable toxicity. A phase II study was conducted to determine the feasibility of a dose-intense two weekly schedule of capecitabine, oxaliplatin, and...